InformationClinical trials have complex eligibility criteria.
Always talk to your clinician about you’re interest in participating in a trial.
Learn why

Optimise reading forHealth ProfessionalsPatients

RecruitingLast updated:15 August 2023

MajesTEC-2: This phase I study is trying to understand how safe and tolerable, and determine the optimal dose level, of a targeted therapy (teclistamab) when it is administered in different combinations with other cancer drugs in people with multiple myelomaA Multi-arm Phase 1b Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma

Clinical summary

Summary

This non-randomised, open-label study has six experimental arm all evaluating different treatment regimens. In Experimental Arm A, participants will receive a treatment regimen of Teclistamab + Daratumumab + Pomalidomide. In Experimental Arm B, participants will receive Teclistamab + Daratumumab + Lenalidomide + Bortezomib (21-day Cycles). In Experimental Arm C, participants will receive Teclistamab + Nirogacestat. In Experimental Arm D, participants will receive Teclistamab + Lenalidomide. In Experimental Arm E, participants will receive Teclistamab + Daratumumab + Lenalidomide. In Experimental Arm F, participants will receive Teclistamab + Daratumumab + Lenalidomide + Bortezomib (28-day Cycles).

Age

People18+

Phase

I

Trial Acronym

MajesTEC-2

More information

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Commercial Sponsor

Janssen Research & Development, LLC

Scientific Title

A Multi-arm Phase 1b Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma

Eligibility

Inclusion

  • You have certain types of non-cancer medical conditions.
  • You have had certain treatments, surgical procedures or drugs.

Exclusion

  • You have been diagnosed with cancer, but have not received any treatment.
  • You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
  • You have had treatment, but your cancer has come back.
Message

Clinical trials have complex eligibility criteria.

Ask your doctor if this trial could be right for you.

Participating hospitals

Recruiting hospitals

InformationTell us if you find this trial availability is not accurate.Report inaccuracy

Get Support

Example

Cancer Connect

Speak with someone who has cancer clinical trial experience.

Learn more

Example

Cancer Council’s cancer nurses

If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council’s experienced cancer nurses on 131120.

Learn more

Example

Information for family, friends and carers

When you are considering a cancer clinical trial, it is a good idea to discuss it with your family, friends or carers.

Learn more